Johan Fransson

This inventor holds 17 USPTO granted patents and 5 published patent applications and 4 EPO patents, primarily in Antibody Engineering. Top assignees: Janssen Biotech, Inc., Centocor Ortho Biotech Inc., Boehringer Ingelhei International Gmbh. Active years: 2012-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Johan Fransson. Retrieved from https://idiyas.com/inventor/johan-fransson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 17 (Patent Applications = 5)

% Patents Active = 70.6

EPO Patents = 4 (Patent Applications = 9)

Average Co-Inventor Count = 6.5

ph-index = 4

Forward Citations = 68(Granted Patents)

Location History:

San Diego, CA (US) (2012 - 2017)
Toronto, CA (2019 - 2023)

Company Filing History:

10 out of 436

Janssen Biotech, Inc.

patents

3 out of 31

Centocor Ortho Biotech Inc.

patents

1 out of 1

Boehringer Ingelhei International Gmbh

patent

4. 1 out of 1

Boehringer Ingelheim Io Canada Inc.

patent

5. 1 out of 1

Fundacio Privada Institucio Catalana De Recerca I

patent

6. 1 out of 1

Fundacio Privada Institut D'investigacio Oncologic

8. 1 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 2012-2026

Loading Chart...

Areas of Expertise:

Anti-CD27 Antibodies

Anti-IL-13 Antibodies

Osteoarthritis Treatment

Nucleic Acids

FLT3 Agonist

LIF Antibodies

T-Cell Proliferation

Affinity Maturation

Dimeric Proteins

Human Antibodies

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12767708 - ANTI-PERIOSTIN ANTIBODIES AND USES THEREOF (2026-10-20),

2. 12473365 - FLT3 AGONIST ANTIBODIES AND USES THEREOF (2025-11-18),

3. 11732050 - Neutralizing human anti-CD27 antibodies (2023-08-22),

4. 11421037 - Nucleic acids encoding anti-CD154 antibodies (2022-08-23),

5. 11390670 - Antibodies against LIF and uses thereof (2022-07-19),

6. 10941197 - Method of treating osteoarthritis with human oncostatin M antibodies (2021-03-09),

7. 10689453 - Methods of inhibiting naive T-cell proliferation using anti-CD27 antibodies (2020-06-23),

8. 10669343 - Anti-CD154 antibodies and methods of using them (2020-06-02),

9. 10544229 - Agonistic antibodies specifically binding CD40 and methods of use (2020-01-28),

10. 10301392 - Methods of inhibiting T-cell mediated B-cell antibody production using anti-CD27 antibodies (2019-05-28),

11. 9683046 - Nucleic acid molecules encoding anti-CD27 antibodies (2017-06-20),

12. 9163083 - Human oncostatin M antibodies (2015-10-20),

13. 9102737 - Human anti-CD27 antibodies, methods and uses (2015-08-11),

14. 8728985 - Display of disulfide linked dimeric proteins in filamentous phage (2014-05-20),

15. 8580714 - Methods of affinity maturing antibodies (2013-11-12),

Title: Innovations of Johan Fransson

Introduction

Johan Fransson is a notable inventor based in Toronto, Canada, recognized for his significant contributions to the field of biotechnology. With a total of 15 patents to his name, he has made remarkable advancements in the development of therapeutic antibodies.

Latest Patents

Fransson's latest patents include the invention of neutralizing human anti-CD27 antibodies. These human antibodies are designed to block the binding of CD27 to its ligand CD70, effectively neutralizing the bioactivity of CD27. This includes inhibiting CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, and alleviating antibody responses. Additionally, these antibodies can stimulate tumor cells by CD70 and promote the production of soluble mediators from T and B-cells. They hold potential for diagnosing or treating diseases associated with CD27 activity. Another significant patent involves nucleic acids encoding anti-CD154 antibodies. This invention relates to antagonistic antibodies that specifically bind to CD154, along with polynucleotides encoding these antibodies or their fragments, and methods for their production and use.

Career Highlights

Throughout his career, Johan Fransson has worked with prominent companies in the biotechnology sector, including Janssen Biotech, Inc. and Centocor Ortho Biotech Inc. His work has significantly impacted the development of therapeutic solutions in immunology.

Collaborations

Fransson has collaborated with esteemed colleagues such as Alexey Teplyakov and Juan C Almagro, contributing to the advancement of innovative biotechnological solutions.

Conclusion

Johan Fransson's contributions to biotechnology through his patents and collaborations highlight his role as a leading inventor in the field. His work continues to influence the development of therapeutic antibodies and their applications in medicine.

Profile summary based on public USPTO records.